STEVEN GUNDERSON: Open Payments
NPI 1790407286 · TALBOTT, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,475 in 89 payments from 19 companies in 2025. Trend: 2023 $2,075 · 2024 $2,522 · 2025 $1,475
Food & beverage: $1,475
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $313 |
| ABBVIE INC. | 18 | $219 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $209 |
| AstraZeneca Pharmaceuticals LP | 10 | $199 |
| Otsuka America Pharmaceutical, Inc. | 10 | $169 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| E.R. Squibb & Sons, L.L.C. | 2 | $36 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| PFIZER INC. | 2 | $31 |
Products named: CAPLYTA, REXULTI, Ozempic, Rybelsus, FARXIGA, Wegovy, AIRSUPRA, UBRELVY.
Industry payments across TN — which companies pay providers there.
